Edition:
United States

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

12.94USD
21 May 2018
Change (% chg)

-- (--)
Prev Close
$12.94
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
81,508
52-wk High
$15.08
52-wk Low
$5.45

Chart for

About

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $604.05
Shares Outstanding(Mil.): 49.15
Dividend: --
Yield (%): --

Financials

  CCXI.OQ Industry Sector
P/E (TTM): 58.39 28.56 32.59
EPS (TTM): 0.22 -- --
ROI: 13.43 13.05 12.60
ROE: 40.19 14.79 14.49

BRIEF-Chemocentryx Q1 Revenue $9.5 Million Versus $8.2 Million

* CHEMOCENTRYX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

May 09 2018

BRIEF-Chemocentryx Q4 Revenue $56.3 Million Versus $4.9 Million

* CHEMOCENTRYX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

Mar 09 2018

BRIEF-Chemocentryx Secures Up To $100 Million In New Capital Commitments

* CHEMOCENTRYX SECURES UP TO $100 MILLION IN NEW CAPITAL COMMITMENTS

Jan 04 2018

BRIEF-ChemoCentryx Says EMA Accepts Vasculitis Drug Avacopan For Conditional Review

* AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage:

Jan 04 2018

Earnings vs. Estimates